JP2024516173A5 - - Google Patents
Info
- Publication number
- JP2024516173A5 JP2024516173A5 JP2023564584A JP2023564584A JP2024516173A5 JP 2024516173 A5 JP2024516173 A5 JP 2024516173A5 JP 2023564584 A JP2023564584 A JP 2023564584A JP 2023564584 A JP2023564584 A JP 2023564584A JP 2024516173 A5 JP2024516173 A5 JP 2024516173A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- mlpscs
- composition according
- million
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021901214 | 2021-04-23 | ||
| AU2021901214A AU2021901214A0 (en) | 2021-04-23 | Method for treating acute respiratory distress syndrome (ARDS) using mesenchymal lineage precursor or stem cells | |
| AU2021902180A AU2021902180A0 (en) | 2021-07-15 | Method for treating acute respiratory distress syndrome (ARDS) using mesenchymal lineage precursor or stem cells | |
| AU2021902180 | 2021-07-15 | ||
| AU2022900260 | 2022-02-09 | ||
| AU2022900260A AU2022900260A0 (en) | 2022-02-09 | Method for treating acute respiratory distress syndrome (ARDS) in specific patients using mesenchymal lineage precursor or stem cells | |
| AU2022900372A AU2022900372A0 (en) | 2022-02-18 | Method for treating acute respiratory distress syndrome (ARDS) using mesenchymal lineage precursor or stem cells | |
| AU2022900372 | 2022-02-18 | ||
| PCT/IB2022/053762 WO2022224206A1 (en) | 2021-04-23 | 2022-04-22 | Method for treating acute respiratory distress syndrome (ards) in specific patients using mesenchymal lineage precursor or stem cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516173A JP2024516173A (ja) | 2024-04-12 |
| JP2024516173A5 true JP2024516173A5 (enExample) | 2025-05-01 |
Family
ID=81585202
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564582A Pending JP2024516172A (ja) | 2021-04-23 | 2022-04-22 | 間葉系前駆体又は幹細胞を使用する急性呼吸窮迫症候群（ａｒｄｓ）を治療するための方法 |
| JP2023564584A Pending JP2024516173A (ja) | 2021-04-23 | 2022-04-22 | 間葉系前駆体又は幹細胞を使用する特定の患者における急性呼吸窮迫症候群（ａｒｄｓ）を治療するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564582A Pending JP2024516172A (ja) | 2021-04-23 | 2022-04-22 | 間葉系前駆体又は幹細胞を使用する急性呼吸窮迫症候群（ａｒｄｓ）を治療するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20240207323A1 (enExample) |
| EP (2) | EP4326295A1 (enExample) |
| JP (2) | JP2024516172A (enExample) |
| KR (2) | KR20240001172A (enExample) |
| AU (2) | AU2022260822A1 (enExample) |
| BR (2) | BR112023021840A2 (enExample) |
| CA (2) | CA3216129A1 (enExample) |
| WO (2) | WO2022224206A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4663241A3 (en) | 2010-10-08 | 2026-03-25 | Mesoblast International Sàrl | Enhanced msc preparations |
| AU2018372631B2 (en) | 2017-11-22 | 2025-06-05 | Mesoblast International Sarl | Cellular compositions and methods of treatment I |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US6251295B1 (en) | 1998-01-08 | 2001-06-26 | Nexell Therapeutics Inc. | Method for recirculation washing of blood cells |
| MX2021014742A (es) * | 2019-06-05 | 2022-02-11 | Univ Emory | Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus. |
-
2022
- 2022-04-22 AU AU2022260822A patent/AU2022260822A1/en active Pending
- 2022-04-22 US US18/556,845 patent/US20240207323A1/en active Pending
- 2022-04-22 BR BR112023021840A patent/BR112023021840A2/pt unknown
- 2022-04-22 JP JP2023564582A patent/JP2024516172A/ja active Pending
- 2022-04-22 AU AU2022261504A patent/AU2022261504A1/en active Pending
- 2022-04-22 KR KR1020237039592A patent/KR20240001172A/ko active Pending
- 2022-04-22 US US18/556,827 patent/US20240197787A1/en active Pending
- 2022-04-22 BR BR112023021825A patent/BR112023021825A2/pt unknown
- 2022-04-22 JP JP2023564584A patent/JP2024516173A/ja active Pending
- 2022-04-22 WO PCT/IB2022/053762 patent/WO2022224206A1/en not_active Ceased
- 2022-04-22 CA CA3216129A patent/CA3216129A1/en active Pending
- 2022-04-22 EP EP22724876.2A patent/EP4326295A1/en active Pending
- 2022-04-22 KR KR1020237039593A patent/KR20240001173A/ko active Pending
- 2022-04-22 WO PCT/IB2022/053763 patent/WO2022224207A1/en not_active Ceased
- 2022-04-22 CA CA3216121A patent/CA3216121A1/en active Pending
- 2022-04-22 EP EP22721854.2A patent/EP4326294A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Osei et al. | Current perspectives on the role of interleukin-1 signalling in the pathogenesis of asthma and COPD | |
| Lacy et al. | Eosinophil cytokines | |
| Gurczynski et al. | IL-17 in the lung: the good, the bad, and the ugly | |
| Mao et al. | Intravenous delivery of bone marrow-derived endothelial progenitor cells improves survival and attenuates lipopolysaccharide-induced lung injury in rats | |
| Nagai et al. | Interferon-γ and tumor necrosis factor-α protect mice from invasive aspergillosis | |
| Strieter et al. | Human alveolar macrophage gene expression of interleukin-8 by tumor necrosis factor-α, lipopolysaccharide, and interleukin-1 β | |
| Standiford et al. | Regulation of human alveolar macrophage-and blood monocyte-derived interleukin-8 by prostaglandin E2 and dexamethasone | |
| Adar et al. | From airway inflammation to inflammatory bowel disease: eotaxin-1, a key regulator of intestinal inflammation | |
| Ayala et al. | Role of Interleukin 6 and Transforming Growth Factor–β in the Induction of Depressed Splenocyte Responses Following Sepsis | |
| Cooke et al. | Acute lung injury after allogeneic stem cell transplantation: is the lung a target of acute graft-versus-host disease? | |
| Spanakis et al. | Cytokine serum levels in patients with chronic HCV infection | |
| Khanam et al. | Abnormal innate immunity in acute-on-chronic liver failure: immunotargets for therapeutics | |
| El-Asrar et al. | Chemokines in the limbal form of vernal keratoconjunctivitis | |
| Hachem et al. | Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure | |
| Frankovich et al. | High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin's disease: atopy predicts idiopathic diffuse lung injury syndromes | |
| Chen et al. | Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infection | |
| Su et al. | Dual proinflammatory and antiviral properties of pulmonary eosinophils in respiratory syncytial virus vaccine-enhanced disease | |
| Mersmann et al. | Preconditioning by toll-like receptor 2 agonist Pam3CSK4 reduces CXCL1-dependent leukocyte recruitment in murine myocardial ischemia/reperfusion injury | |
| Oesterreicher et al. | Increased in vitro production and serum levels of the soluble lipopolysaccharide receptor sCD14 in liver disease | |
| Tong et al. | Deep hypothermia therapy attenuates LPS-induced microglia neuroinflammation via the STAT3 pathway | |
| JP2023520233A5 (enExample) | ||
| Hu et al. | Interleukin‐18 expression increases in the aorta and plasma of patients with acute aortic dissection | |
| JP2013508408A5 (enExample) | ||
| Sarmiento et al. | Ruxolitinib for severe COVID-19-related hyperinflammation in nonresponders to steroids | |
| JP2024516172A5 (enExample) |